Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19

被引：9

作者：

Nakamura, Hideta ^{[1
]}

Miyagi, Kazuya ^{[1
]}

Otsuki, Mariko ^{[1
]}

Higure, Yuuri ^{[1
]}

Nishiyama, Naoya ^{[1
]}

Kinjo, Takeshi ^{[1
]}

Nakamatsu, Masashi ^{[1
]}

Haranaga, Shusaku ^{[1
]}

Tateyama, Masao ^{[1
]}

Fujita, Jiro ^{[1
]}

机构：

[1] Univ Ryukyus, Grad Sch Med, Dept Infect Dis Resp & Digest Med, Nishihara, Okinawa, Japan

来源：

INTERNAL MEDICINE | 2020年 / 59卷 / 22期

关键词：

COVID-19; tocilizumab; acute hypertriglyceridaemia;

D O I：

10.2169/internalmedicine.5244-20

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.

引用

页码：2945 / 2949

页数：5

共 14 条

[1] Brigatto AP, 2018, NUTRITION, V55, P7
[2] Cacciapaglia F, MEDIATORS INFLAMM
[3] Hypertriglyceridemia: a potential side effect of propofol sedation in critical illness
Devaud, J. -C.
Berger, M. M.
Pannatier, A.
Marques-Vidal, P.
Tappy, L.
Rodondi, N.
Chiolero, R.
Voirol, P.
[J]. INTENSIVE CARE MEDICINE, 2012, 38 (12) : 1990 - 1998
[4] Di Giambenedetto S, J MED VIROL
[5] Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System
Flaig, T.
Douros, A.
Bronder, E.
Klimpel, A.
Kreutz, R.
Garbe, E.
[J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (06) : 718 - 721
[6] Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial
Giles, Jon T.
Sattar, Naveed
Gabriel, Sherine
Ridker, Paul M.
Gay, Steffen
Warne, Charles
Musselman, David
Brockwell, Laura
Shittu, Emma
Klearman, Micki
Fleming, Thomas R.
[J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72 (01) : 31 - 40
[7] Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis
Hoffman, Elinoar
Rahat, Michal A.
Feld, Joy
Elias, Muna
Rosner, Itzhak
Kaly, Lisa
Lavie, Idit
Gazitt, Tal
Zisman, Devy
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (18)
[8] FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Le, Robert Q.
Li, Liang
Yuan, Weishi
Shord, Stacy S.
Nie, Lei
Habtemariam, Bahru A.
Przepiorka, Donna
Farrell, Ann T.
Pazdur, Richard
[J]. ONCOLOGIST, 2018, 23 (08) : 943 - 947
[9] Tocilizumab treatment in COVID-19: A single center experience
Luo, Pan
Liu, Yi
Qiu, Lin
Liu, Xiulan
Liu, Dong
Li, Juan
[J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (07) : 814 - 818
[10] Cytokine release syndrome in severe COVID-19
Moore, John B.
June, Carl H.
[J]. SCIENCE, 2020, 368 (6490) : 473 - 474

← 1 2 →